Connor, Clark & Lunn Investment Management Ltd. Morphic Holding, Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$18.8 Billion
Q3 2024

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	SELL	$26.12 - $34.07 $1.22 Million - $1.59 Million	-46,665 Reduced 44.6%	57,965 $1.97 Million
Q1 2024 May 09, 2024	BUY	$26.64 - $40.31 $1.89 Million - $2.85 Million	70,763 Added 208.94%	104,630 $3.68 Million
Q4 2023 Feb 09, 2024	BUY	$19.95 - $31.0 $675,646 - $1.05 Million	33,867 New	33,867 $978,000
Q1 2023 May 09, 2023	SELL	$26.01 - $48.69 $201,083 - $376,422	-7,731 Reduced 25.41%	22,689 $854,000
Q4 2022 Feb 10, 2023	SELL	$24.14 - $30.37 $443,862 - $558,413	-18,387 Reduced 37.67%	30,420 $813,000
Q3 2022 Nov 10, 2022	BUY	$22.23 - $33.37 $453,892 - $681,348	20,418 Added 71.92%	48,807 $1.38 Million
Q2 2022 Aug 05, 2022	BUY	$19.74 - $43.01 $560,398 - $1.22 Million	28,389 New	28,389 $616,000

Others Institutions Holding MORF

# of Institutions

Shares Held

4.7M

Call Options Held

Put Options Held

View Full List

About Morphic Holding, Inc.

Ticker MORF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,477,100
Market Cap $2.19B
Description
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical ...

More about MORF

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account